secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001104659-24-037318
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical reports FY2023 revenue $79.2M (+7% YoY); net loss narrows to $3.9M from $29.6M
--------------------------------------------------------------------------------

- Total revenues $79.2M vs $73.7M in 2022; growth driven by $19.0M Maruho licensing revenue.
- Net product revenues fell 16% to $59.7M due to generic competition and Ximino discontinuation.
- Net loss improved to $3.9M ($0.21 loss per share) from $29.6M ($1.69 loss per share) in 2022.
- Adjusted EBITDA turned positive to $15.6M ($0.85 basic EPS) from negative $7.3M in 2022.
- NDA for rosacea candidate DFD-29 accepted by FDA; PDUFA goal date set for November 4, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465924037318/0001104659-24-037318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465924037318/tm249442d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-037318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer